Everolimus drug page Clinical trials

Trials with Everolimus

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

20Trials
2Recruiting
17Countries
2.853Planned patients

Showing 1–20 of 20

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Recruiting Phase 2 40 patients NCT05725200

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or ha…

Norway Sept 2022 – Dec 2040 Interventional
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Recruiting Phase 2 900 patients NCT02029001

The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated second line…

France Mar 2014 – Oct 2027 Interventional
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)
Not yet recruiting Phase 1 38 patients NCT07435584

This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.

Mar 2026 – Dec 2028 Interventional
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
Not yet recruiting Phase 2 25 patients NCT06301386

The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected. The main question is to explore the survival tim…

China Apr 2024 – Dec 2026 Interventional
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Ongoing, not recruiting Phase 1 610 patients NCT04185883

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

United States, Australia, Austria, Belgium and 6 more Dec 2019 – Dec 2027 Interventional
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Finished Phase 1 93 patients NCT03065387

This phase I trial studies the side effects and best dose of neratinib in combination with everolimus, palbociclib, or trametinib in participants with solid tumors with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutat…

United States Oct 2017 – Oct 2028 Interventional
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Finished Phase 1 298 patients NCT02890069

The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, ph…

United States, Germany, Netherlands, South Korea and 3 more Oct 2016 – Feb 2022 Interventional
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Finished Phase 1 263 patients NCT02599324

The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gas…

United States, South Korea, Spain, United Kingdom Dec 2015 – Aug 2021 Interventional
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
Finished Phase 1 19 patients NCT01149434

The study consists of two parts: Drug Interaction (Pharmacokinetic) Phase and Pharmacodynamic Phase The primary study objective for the Drug Interaction Study is to determine the pharmacokinetic interactions between RAD001 and JI-101. Th…

United States Sept 2010 – Aug 2012 Interventional
Combined with: JI-101
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Finished Phase 1 18 patients NCT01154335

The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.

United States Jul 2010 – May 2013 Interventional
Combined with: OSI-906
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
Finished Phase 1 49 patients NCT01139138

This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer

Australia Jun 2010 – Jun 2017 Interventional
Combined with: IrinotecanPanitumumab
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Finished Phase 1 56 patients NCT01058655

Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular endothelial growth factor (VEGF) is one of the cell pathways u…

United States Feb 2010 – Apr 2015 Interventional
Combined with: Tivozanib
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
Finished Phase 2 100 patients NCT01387880

This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat sarcoma viral …

Denmark Jan 2010 – Mar 2012 Interventional
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Finished Phase 1 12 patients NCT01637194

This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer. Monoclonal antibodies, such as cetuximab, ca…

United States Nov 2008 – Jul 2011 Interventional
Combined with: Cetuximab
Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
Finished Phase 2 50 patients NCT00597506

The purpose of this study is to find the safest and most effective dose of the drugs bevacizumab and everolimus given in combination for the treatment of metastatic colorectal cancer. Bevacizumab (also called Avastin™) is a drug that is gi…

United States Oct 2007 – Jun 2010 Interventional
Combined with: Bevacizumab
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Finished Phase 1 41 patients NCT00522665

The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may increase efficacy for patients with metastatic colorectal cancer who progressed on prior chemotherapy. This approach is biologically directed to …

United States Aug 2007 – Feb 2015 Interventional
Combined with: CetuximabIrinotecan
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Finished Phase 1 19 patients NCT00478634

This study will assess the safety of RAD001 when given together with cetuximab and irinotecan

United States May 2007 – Sept 2009 Interventional
Combined with: CetuximabIrinotecan
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Finished Phase 2 199 patients NCT00419159

To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.

United States Dec 2006 – Mar 2009 Interventional
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
Finished Phase 2 1 patients NCT00390364

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patien…

United States Oct 2006 – Oct 2007 Interventional
Phase II Trial of RAD001 in Refractory Colorectal Cancer
Finished Phase 2 22 patients NCT00337545

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

United States May 2006 – Apr 2007 Interventional

Where the recruiting trials are